Role of Small Dense Low-density Lipoprotein Cholesterol in Cardiovascular Events in Patients with Coronary Artery Disease and Type 2 Diabetes Mellitus Receiving Statin Treatment-Reference-Cited by-同舟云学术

Role of Small Dense Low-density Lipoprotein Cholesterol in Cardiovascular Events in Patients with Coronary Artery Disease and Type 2 Diabetes Mellitus Receiving Statin Treatment

Published:2023 Issue: Volume: Page:
ISSN:1340-3478
Container-title:Journal of Atherosclerosis and Thrombosis
language:en
Short-container-title:JAT

Author:

Yamaji Takayuki¹,Harada Takahiro¹,Kajikawa Masato²,Maruhashi Tatsuya³,Kishimoto Shinji³,Yusoff Farina Mohamad³,Chayama Kazuaki⁴,Goto Chikara⁵,Nakashima Ayumu²,Tomiyama Hirofumi⁶,Takase Bonpei⁷,Kohro Takahide⁸,Suzuki Toru⁹,Ishizu Tomoko¹⁰,Ueda Shinichiro¹¹,Yamazaki Tsutomu¹²,Furumoto Tomoo¹³,Kario Kazuomi¹⁴,Inoue Teruo¹⁵,Watanabe Kentaro¹⁶,Takemoto Yasuhiko¹⁷,Hano Takuzo¹⁸,Sata Masataka¹⁹,Ishibashi Yutaka²⁰,Node Koichi²¹,Maemura Koji²²,Ohya Yusuke²³,Furukawa Taiji²⁴,Ito Hiroshi²⁵,Yamashina Akira⁶,Koba Shinji²⁶,Higashi Yukihito²

Affiliation:

1. Department of Cardiovascular Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University

2. Division of Regeneration and Medicine, Medical Center for Translational and Clinical Research, Hiroshima University Hospital

3. Department of Cardiovascular Regeneration and Medicine, Research Institute for Radiation Biology and Medicine, Hiroshima University

4. Department of Gastroenterology and Metabolism, Institute of Biomedical and Health Sciences, Graduate School of Biomedical and Health Sciences, Hiroshima University

5. Department of Physical Therapy, Hiroshima International University

6. Department of Cardiology, Tokyo Medical University

7. Division of Biomedical Engineering, National Defense Medical College Research Institute

8. Department of Clinical Informatics, Jichi Medical University School of Medicine

9. Cardiovascular Medicine, University of Leicester

10. Cardiovascular Division, Institute of Clinical Medicine, University of Tsukuba

11. Department of Clinical Pharmacology and Therapeutics, University of the Ryukyu School of Medicine

12. Department of Clinical Epidemiology and Systems, Faculty of Medicine, The University of Tokyo

13. Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine

14. Division of Cardiovascular Medicine, Jichi Medical University School of Medicine

15. Department of Cardiovascular Medicine, Dokkyo Medical University

16. Department of Neurology, Hematology, Metabolism, Endocrinology and Diabetelogy (DNHMED), Yamagata University School of Medicine

17. Department of Internal Medicine and Cardiology, Osaka Metropolitan University Graduate School of Medicine

18. Department of Medical Education and Population-based Medicine, Postgraduate School of Medicine, Wakayama Medical University

19. Department of Cardiovascular Medicine, Institute of Health Biosciences, The University of Tokushima Graduate School

20. Department of General Medicine, Shimane University Faculty of Medicine

21. Department of Cardiovascular and Renal Medicine, Saga University

22. Department of Cardiovascular Medicine, Course of Medical and Dental Sciences, Graduate School of Biomedical Sciences, Nagasaki University

23. The Third Department of Internal Medicine, University of the Ryukyus

24. Department of Internal Medicine, Teikyo University School of Medicine

25. Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

26. Department of Medicine, Division of Cardiology, Showa University School of Medicine

Publisher

Japan Atherosclerosis Society

Subject

Biochemistry (medical),Cardiology and Cardiovascular Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/jat/advpub/0/advpub_64416/_pdf

Reference40 articles.

1. 1) Haffner SM, Lehto S, Rönnemaa T, Pyörälä K and Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. The New England journal of medicine, 1998; 339: 229-234

2. 2) 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2019. Diabetes Care, 2019; 42: S103-s123

3. 3) Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA and Skene AM: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. The New England journal of medicine, 2004; 350: 1495-1504

4. 4) Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, Eisenberg D, Shurzinske L and McCormick LS: Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. The New England journal of medicine, 1999; 341: 70-76

5. 5) Kajikawa M, Maruhashi T, Kishimoto S, Matsui S, Hashimoto H, Takaeko Y, Yusoff FM, Kihara Y, Chayama K, Goto C, Noma K, Nakashima A, Tomiyama H, Takase B, Kohro T, Suzuki T, Ishizu T, Ueda S, Yamazaki T, Furumoto T, Kario K, Inoue T, Koba S, Watanabe K, Takemoto Y, Hano T, Sata M, Ishibashi Y, Node K, Maemura K, Ohya Y, Furukawa T, Ito H, Ikeda H, Yamashina A and Higashi Y: Target of Triglycerides as Residual Risk for Cardiovascular Events in Patients With Coronary Artery Disease - Post Hoc Analysis of the FMD-J Study A. Circulation journal : official journal of the Japanese Circulation Society, 2019; 83: 1064-1071